Bristol-Myers Squibb is now taking Serzone (nefazodone) off the market

June 2004

Bristol-Myers Squibb is now taking Serzone (nefazodone) off the market in the U.S.

It's already off the market in Europe and Canada.

The company is not saying...but liver toxicity seems to be a likely reason. FDA added a black box warning 2 years ago.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Which drug interactions do you really need to worry about
Gastroenterology new warnings about complications from severe diarrhea in patients taking Zelnorm (tegaserod)
Cardiology Does Vioxx (rofecoxib) cause more cardiovascular problems than other NSAIDs
Geriatrics vitamin D might help prevent falls in seniors
Obesity & Weight Loss Hoodia is the latest craze for weight loss
Infectious Diseases new antibiotic, Ketek (telithromycin)
Infectious Diseases Quinolones are losing their effectiveness for gonorrhea
Parkinson's Disease Apokyn (apomorphine) will be available for advanced Parkinson's
Hematology & Oncology Zyprexa (olanzapine) used to prevent nausea and vomiting
Diabetes which glucose meter is best
Diabetes Most diabetes patients should be taking a statin
OTC Products Dulcolax, Kaopectate and other OTCs too often keep the same brand name, but change ingredients
Bristol-Myers Squibb is now taking Serzone (nefazodone) off the market
Women's Health home menopause tests